Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study

Leukemia

Volumn 29, Issue 3, 2015, Pages 548-555

  Ostgard L S G ^a   Norgaard J M ^a   Sengelov H ^b   Severinsen, M ^c,d   Friis, L S ^b   Marcher, C W ^e   Dufva, I H ^f   Norgaard M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMORBIDITY; DENMARK; FEMALE; HUMAN; INTENSIVE CARE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; ADOLESCENT; AGE; CARDIOVASCULAR DISEASES; LEUKEMIA, MYELOID, ACUTE; LUNG DISEASES; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; REMISSION; SURVIVAL; VERY ELDERLY;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUNG DISEASES; MALE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84924412254     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.234     Document Type: Article

References (41)

1. United Nations. Department of Economic and Social Affairs. Population DivisionWorld population prospects. The 2010 Revision. United Nations: New York, NY, USA, 2011. Report no. ST/ESA/SER.A/313.
2. Ferrara F. Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. Clin Lymphoma Myeloma Leuk 2011; 11: 10-16.
3. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179-4187.
4. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
5. Ording AG, Sorensen HT. Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. Clin Epidemiol 2013; 5: 199-203.
6. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
7. Gangatharan SA, Grove CS, P'ng S, O'Reilly J, Joske D, Leahy MF et al. Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. Intern Med J 2013; 43: 903-911.
8. Juliusson GSwedish AML Group. Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood 2011; 117: 3473-3474.
9. Ostgard LSG, Norgaard M, Sengelov H, Kjeldsen L, Friis LS, Jensen MK et al. Do results from clinical trials in acute myeloid leukemia reflect clinical reality? a Danish national cohort study of 813 patients. ASH Annu Meet Abstr 2012; 120: 1477.
10. Population and elections - StatBank Denmark - data and statistics 2012; available at www.statbank.dk.
11. Østgård L, Nørgaard J, Severinsen M, Friis L, Jensen M, Nielsen O et al. Data quality in the danish national acute leukemia registry: a hematological data resource. Clin Epidemiol 2013; 5: 335-344.
12. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027-1036.
13. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
14. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-268.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
16. Nguyen-Nielsen M, Norgaard M, Jacobsen JB, Borre M, Thomsen RW, Sogaard M. Comorbidity and survival of Danish prostate cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol 2013; 5: 47-55.
17. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013; 5: 3-29.
18. Ording AG, Cronin-Fenton DP, Jacobsen JB, Norgaard M, Thomsen RW, Christiansen P et al. Comorbidity and survival of Danish breast cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol 2013; 5: 39-46.
19. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010; 21: 114-119.
20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22. Eastern Cooperative Oncology GroupECOG Performance Status. available at http://www.ecog.org/general/perf-stat.html2006.
23. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
24. Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 2398-2399.
25. Stata Data Analysis and Statistical SoftwareStataCorp LP. What's new in statistical software 2013; Availible at http://www.stata.com/stata12/multiple-imputation.
26. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009; 28: 1982-1998.
27. Rising B. Multiple imputation. Italian StataCorp LP: Bologa, Romania, 2010.
28. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci 2007; 8: 206-213.
29. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360-3368.
30. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30: 3924-3931.
31. Working Parties on Leukemia in Adults and ChildrenTrial in acute myeloid leukemia or high risk myelodysplastic syndrome 17 2008; available at http://aml17.cardiff.ac.uk.
32. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106: 1090-1098.
33. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012; 97: 1916-1924.
34. Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy 2013; 11: 275-286.
35. Alibhai SM, Leach M, Minden MD, Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 2009; 115: 2903-2911.
36. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007; 136: 624-627.
37. Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008; 93: 1806-1813.
38. Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk 2011; 11 (Suppl 1): S54-S59.
39. Bacher U, Haferlach T. The benefit of population-based studies for older patients with acute myeloid leukemia. Haematologica 2012; 97: 1781-1782.
40. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 2012; 119: 3890-3899.
41. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.